EMA Authorised: Zilbrysq (zilucoplan) — UCB Pharma S.A.

View source ↗

Summary

Zilbrysq (zilucoplan) has been authorised by the EMA for use in myasthenia gravis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• ZILBRYSQ (ZILUCOPLAN)

Snippet

Status: Authorised. Therapeutic area: Myasthenia Gravis. MAH: UCB Pharma S.A.. Decision date: 09/07/2026